Skip to main content

Using the Body's Own Immune System and On and Off Switches to Vaccinate Patients Against Their Cancer


Mount Sinai’s Thomas Marron, MD, PhD, discusses patient response to a vaccine that combines local low-dose radiation, intramural Flt3L, which stimulates dendritic cells, and intravenous poly-ICLC, an immune stimulating factor, with the PD-1 inhibitor pembrolizumab (KEYTRUDA®).

Learn More